Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Rocky Mountain spotted fever refers to an infection caused by the bacterium Rickettsia rickettsia. This particular bacterium is carried by certain species of ticks and spread to humans through the bites of infected ticks. Signs and symptoms of the condition generally develop approximately 2 to 14 days following the tick bite and may include fever, rash, headache, muscle pain, chills, and/or confusion. Some affected people may also experience diarrhea, nausea, vomiting, light sensitivity, hallucinations, and/or excessive thirst. Most cases occur in the spring and summer and are found in children. Risk factors for developing the conditioninclude recent hiking or exposure to ticks in an area where the disease is known to occur. Rocky Mountain spotted fever is typically treated with antibiotics (such as doxycycline or tetracycline).
Biomarker and diagnostic research for Rocky mountain spotted fever has been reported in the published literature.
1 FDA-approved treatment is available for Rocky mountain spotted fever, including MINOCYCLINE HYDROCHLORIDE (MINOCIN, approved 1972).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for Rocky mountain spotted fever.
139 publications have been identified in PubMed for Rocky mountain spotted fever. Research spans Epidemiology / Natural History (38%), Basic Science / Preclinical (21%), and Review / Meta-Analysis (19%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 43 | 38% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 5:49 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Rocky mountain spotted fever
MINOCIN
MINOCYCLINE HYDROCHLORIDE |
— |
1972 |
Available |
Gene therapy approaches for Rocky mountain spotted fever have been reported in the published literature.
View trials for Rocky mountain spotted fever
Laboratory research
24 |
21% |
Research summaries | 21 | 19% |
Patient case studies | 11 | 10% |
New treatment approaches | 6 | 5% |
Other research | 4 | 4% |
Testing and diagnosis research | 3 | 3% |
Pasini-Martins M (2026). [PMID: 41830990](https://pubmed.ncbi.nlm.nih.gov/41830990/). *Exp Appl Acarol*. [Epidemiology / Natural History]
Kobbekaduwa VC (2026). [PMID: 41370177](https://pubmed.ncbi.nlm.nih.gov/41370177/). *J Med Entomol*. [Epidemiology / Natural History]
Vandegriff CW (2026). [PMID: 41644590](https://pubmed.ncbi.nlm.nih.gov/41644590/). *Sci Rep*. [Basic Science / Preclinical]
Rojas Landa CA (2026). [PMID: 41994746](https://pubmed.ncbi.nlm.nih.gov/41994746/). *Cureus*. [Case Report / Case Series]
Chagas ACS (2026). [PMID: 41719889](https://pubmed.ncbi.nlm.nih.gov/41719889/). *Vet Parasitol*. [Basic Science / Preclinical]
Stoll IM (2026). [PMID: 42114410](https://pubmed.ncbi.nlm.nih.gov/42114410/). *Int J Med Microbiol*. [Basic Science / Preclinical]
Chaugne É (2026). [PMID: 42083847](https://pubmed.ncbi.nlm.nih.gov/42083847/). *Rev Prat*. [Review / Meta-Analysis]
Miller I (2026). [PMID: 39657729](https://pubmed.ncbi.nlm.nih.gov/39657729/). *J Hist Med Allied Sci*. [Epidemiology / Natural History]
Alhamaid YA (2026). [PMID: 41943529](https://pubmed.ncbi.nlm.nih.gov/41943529/). *Ann Afr Med*. [Epidemiology / Natural History]
León-Espinosa GA (2026). [PMID: 41877385](https://pubmed.ncbi.nlm.nih.gov/41877385/). *Zoonoses Public Health*. [Epidemiology / Natural History]
AI-curated news mentioning Rocky mountain spotted fever
Updated Jun 19, 2015
A study highlights the economic burden of Rocky Mountain spotted fever (RMSF) among American Indian tribes in Arizona, estimating $13.2 million in losses from 2002 to 2011. Experts advocate for enhanced prevention and control efforts to mitigate premature death and disability.